quinoxalines has been researched along with Cognition Disorders in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ago, Y; Araki, R; Hasebe, S; Matsuda, T; Nishiyama, S; Oka, S; Takuma, K; Tanaka, T | 1 |
| Becker, C; Bencherif, M; Kucinski, A; Lippiello, P; Stachowiak, EK; Stachowiak, MK; Wersinger, S | 1 |
| Cheng, Q; Li, L; Ma, Y; Wang, E; Zhang, X | 1 |
| Herman, AI; Mooney, M; Sofuoglu, M; Waters, AJ | 1 |
| Cho, DM; Jung, DU; Jung, SS; Kang, JW; Kelly, DL; Kim, SD; Kong, BG; Lee, JH; Lee, SW; McMahon, RP; Oh, MK; Seo, YS; Shim, JC | 1 |
| Garg, PK; Garg, S; Gould, RW; Nader, MA | 1 |
| Cerimele, JM; Durango, A | 1 |
| Belichenko, PV; Epstein, CJ; Kleschevnikov, AM; Malenka, RC; Mobley, WC; Villar, AJ | 1 |
| Freedman, R | 1 |
1 review(s) available for quinoxalines and Cognition Disorders
| Article | Year |
|---|---|
Does varenicline worsen psychiatric symptoms in patients with schizophrenia or schizoaffective disorder? A review of published studies.
Topics: Adverse Drug Reaction Reporting Systems; Attention; Benzazepines; Cognition Disorders; Disease Progression; Dose-Response Relationship, Drug; Humans; Nicotinic Agonists; Psychiatric Status Rating Scales; Psychoses, Substance-Induced; Quinoxalines; Risk Factors; Schizophrenia; Schizophrenic Psychology; Smoking Cessation; Treatment Outcome; Varenicline | 2012 |
2 trial(s) available for quinoxalines and Cognition Disorders
| Article | Year |
|---|---|
Varenicline attenuates some of the subjective and physiological effects of intravenous nicotine in humans.
Topics: Adult; Affect; Benzazepines; Blood Pressure; Cognition Disorders; Cotinine; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Rate; Humans; Injections, Intravenous; Male; Middle Aged; Neuropsychological Tests; Nicotine; Nicotinic Agonists; Quinoxalines; Severity of Illness Index; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2009 |
Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial.
Topics: Adult; Antipsychotic Agents; Benzazepines; Cognition Disorders; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Nicotinic Agonists; Quinoxalines; Schizophrenia; Smoking; Smoking Cessation; Treatment Outcome; Varenicline | 2012 |
6 other study(ies) available for quinoxalines and Cognition Disorders
| Article | Year |
|---|---|
Involvement of prefrontal AMPA receptors in encounter stimulation-induced hyperactivity in isolation-reared mice.
Topics: Aggression; Animals; Animals, Outbred Strains; Cognition Disorders; Depression; Dopamine; Excitatory Amino Acid Antagonists; Hippocampus; Hyperkinesis; Male; Mice; Nucleus Accumbens; Prefrontal Cortex; Quinoxalines; Receptors, AMPA; Serotonin; Social Behavior; Social Isolation | 2014 |
The effects of varenicline on sensory gating and exploratory behavior with pretreatment with nicotinic or 5-HT3A receptor antagonists.
Topics: Animals; Benzazepines; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Exploratory Behavior; Female; Male; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Transgenic; Nicotinic Agonists; Quinoxalines; Receptors, Serotonin, 5-HT3; Reflex, Startle; Schizophrenia; Sensory Gating; Serotonin 5-HT3 Receptor Agonists; Serotonin 5-HT3 Receptor Antagonists; Varenicline | 2015 |
Inhibiting tumor necrosis factor-α signaling attenuates postoperative cognitive dysfunction in aged rats.
Topics: Abdomen; Aging; Animals; Cognition; Cognition Disorders; Gene Expression Regulation; Hippocampus; Humans; Inflammation; Injections, Intraventricular; Interleukin-1beta; Interleukin-4; Interleukin-6; Male; Maze Learning; Postoperative Complications; Quinoxalines; Rats; Rats, Sprague-Dawley; Signal Transduction; Tumor Necrosis Factor-alpha | 2015 |
Effects of nicotinic acetylcholine receptor agonists on cognition in rhesus monkeys with a chronic cocaine self-administration history.
Topics: Animals; Behavior, Animal; Benzamides; Benzazepines; Bridged Bicyclo Compounds; Cocaine; Cocaine-Related Disorders; Cognition Disorders; Dopamine Uptake Inhibitors; Hippocampus; Learning; Ligands; Macaca mulatta; Male; Memory, Short-Term; Nerve Tissue Proteins; Neurons; Nicotine; Nicotinic Agonists; Nootropic Agents; Quinoxalines; Receptors, Nicotinic; Reversal Learning; Self Administration; Varenicline | 2013 |
Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome.
Topics: 2-Amino-5-phosphonovalerate; Animals; Cognition Disorders; Crosses, Genetic; Dentate Gyrus; Disease Models, Animal; Down Syndrome; Evoked Potentials; Female; GABA-A Receptor Antagonists; Gene Dosage; Glycine; Hippocampus; Long-Term Potentiation; Magnesium; Male; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Mutant Strains; Patch-Clamp Techniques; Picrotoxin; Presynaptic Terminals; Quinoxalines; Receptors, N-Methyl-D-Aspartate; Species Specificity; Trisomy | 2004 |
Exacerbation of schizophrenia by varenicline.
Topics: Acute Disease; Benzazepines; Cognition Disorders; Comorbidity; Female; Humans; Middle Aged; Nicotine; Quinoxalines; Recurrence; Schizophrenia; Schizophrenic Psychology; Self Medication; Smoking; Smoking Cessation; Varenicline | 2007 |